Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Toni K. Choueiri"'
Autor:
Brian I. Rini, Javid J. Moslehi, Marc Bonaca, Manuela Schmidinger, Laurence Albiges, Toni K. Choueiri, Robert J. Motzer, Michael B. Atkins, John Haanen, Mariangela Mariani, Jing Wang, Subramanian Hariharan, James Larkin
Publikováno v:
Journal of Clinical Oncology. 40:1929-1938
PURPOSE Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could le
Autor:
Vishal Navani, J Connor Wells, Devon J Boyne, Winson Y Cheung, Darren M Brenner, Bradley A McGregor, Chris Labaki, Andrew L Schmidt, Rana R McKay, Luis Meza, Sumanta K Pal, Frede Donskov, Benoit Beuselinck, Maxwell Otiato, Lisa Ludwig, Thomas Powles, Bernadett E Szabados, Toni K Choueiri, Daniel Y C Heng
BACKGROUND: There are limited data evaluating the activity of cabozantinib (CABO) as second line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno-oncology(IO)/vascular endothelial growth factor inhibitor (VEGFi) combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9fd530a1f2f3ecd64cfa5d480f36f4
https://lirias.kuleuven.be/handle/20.500.12942/717579
https://lirias.kuleuven.be/handle/20.500.12942/717579
Autor:
Paul B. Robbins, Elaine T. Lam, Mehmet Asim Bilen, James Larkin, Alessandra di Pietro, Aly-Khan A. Lalani, Lance C. Pagliaro, Toni K. Choueiri, John B. A. G. Haanen, Eric Voog, Bradley Alexander McGregor, Nikolay Kislov, Bo Huang, Laurence Albiges, Stan Krulewicz, Brian I. Rini, Martin H. Voss
Publikováno v:
Clinical Cancer Research. 28:738-747
Purpose: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. Experimental Design: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component,
Autor:
Brian I Rini, Sabina Signoretti, Toni K Choueiri, David F McDermott, Robert J Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S Tykodi, Sumanta K Pal, Saurabh Gupta, Chung-Wei Lee, Ruiyun Jiang, Nizar M Tannir
Publikováno v:
Rini, B I, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, George, S, Powles, T, Donskov, F, Tykodi, S S, Pal, S K, Gupta, S, Lee, C W, Jiang, R & Tannir, N M 2022, ' Long-Term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Journal for immunotherapy of cancer, vol. 10, no. 12, e005445 . https://doi.org/10.1136/jitc-2022-005445
BackgroundPatients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients
Autor:
Cristina Suarez, Mario Sznol, Richard W. Joseph, Beiying Ding, Ning Leng, Alain Ravaud, John D. Hainsworth, Thomas E. Hutson, Brian I. Rini, David F. McDermott, Sergio Bracarda, Sumanta K. Pal, Allen Lee Cohn, Thomas Powles, Walter M. Stadler, James A. Reeves, Mahrukh Huseni, Christina Schiff, Lawrence Fong, Bernard Escudier, Kenji Hashimoto, Toni K. Choueiri, Michael B. Atkins, Robert J. Motzer
Publikováno v:
European Urology. 79:665-673
Background The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively. Objective To eval
Autor:
Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T. Bourlon, Stephen Huo, Viviana Del Tejo, Ella X. Du, Xiaoran Yang, Keith A. Betts, Toni K. Choueiri, Bradley McGregor
Publikováno v:
Scientia
Advanced Renal Cell Carcinoma; Adverse Events; Nivolumab Carcinoma de células renales avanzado; Eventos adversos; Nivolumab Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab Background and Objectives Novel immunotherapy-bas
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Mahgull Nazar Thakur, Toni K. Choueiri, Michael B. Atkins, David F. McDermott, Igor Puzanov, Jamal Tarazi, Ulka N. Vaishampayan, Kathrine C. Fernandez, Saby George, William T. Duggan, Daniel C. Cho, Rodolfo F. Perini, Elizabeth R. Plimack, Mayer Fishman
Publikováno v:
European Journal of Cancer. 145:1-10
Background Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a randomised phase III trial in patients with advanced renal-cell carcinoma (RCC). We
Autor:
Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid
Publikováno v:
Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063
Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab pl
Autor:
Brian I. Rini, Mauricio Burotto, Bernard Escudier, C-W. Lee, M.-O. Grimm, David F. McDermott, Howard Gurney, Christian K. Kollmannsberger, Saby George, Yoshihiko Tomita, Camillo Porta, Thomas Powles, Elizabeth R. Plimack, M.B. McHenry, Frede Donskov, Toni K. Choueiri, Robert J. Motzer, Hans J. Hammers, Nizar M. Tannir
Publikováno v:
Annals of Oncology. 32:S685-S687